BioCentury
ARTICLE | Finance

Small price of progress

Why French Orphan play InFlectis thinks it can create value while being drip fed

June 13, 2016 7:00 AM UTC

Although European biotechs have long had a problem making progress on small series A rounds, InFlectis BioScience S.A.S. and co-lead investor Remiges Ventures expect that a €4.5 million ($5 million) infusion will get the biotech's lead asset to human safety data, and the safety data will enable a subsequent up-round.

The round was led by CM-CIC Innovation and Remiges, and included Go Capital and Participations Besançon. The investors have an option to increase the round by €1.5 million. ...